UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Anemia in Clinical Practice—Definition and Classification: Does Hemoglobin Change With Aging?

Seminars in hematology, 2015-10, Vol.52 (4), p.261-269

2015

Volltextzugriff (PDF)

β-Thalassemias

The New England journal of medicine, 2021-02, Vol.384 (8), p.727-743

2021

Volltextzugriff (PDF)

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia

The New England journal of medicine, 2021-01, Vol.384 (3), p.252-260

2021

Volltextzugriff (PDF)

Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up

Blood, 2011-07, Vol.118 (4), p.884-893

2011

Volltextzugriff (PDF)

Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in β-thalassemia

Blood, 2008-08, Vol.112 (3), p.875-885

2008

Volltextzugriff (PDF)

New therapeutic targets in transfusion-dependent and -independent thalassemia

Hematology, 2017-12, Vol.2017 (1), p.278-283

2017

Volltextzugriff (PDF)

β-Thalassemias. Reply

The New England journal of medicine, 2021-06, Vol.384 (22), p.2166-2166

2021

Volltextzugriff (PDF)

New insights into transfusion-related iron toxicity: Implications for the oncologist

Critical reviews in oncology/hematology, 2016-03, Vol.99, p.261-271

2016

Volltextzugriff (PDF)

Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload

Blood, 2015-06, Vol.125 (25), p.3868-3877

2015

Volltextzugriff (PDF)

Αlpha-thalassemia: A practical overview

Blood reviews, 2024-03, Vol.64, p.101165-101165, Article 101165

2024

Volltextzugriff (PDF)

The autophagy-activating kinase ULK1 mediates clearance of free α-globin in β-thalassemia

Science translational medicine, 2019-08, Vol.11 (506)

2019

Volltextzugriff (PDF)

Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia

Expert review of hematology, 2013-10, Vol.6 (5), p.495-509

2013

Volltextzugriff (PDF)

Treating iron overload in patients with non‐transfusion‐dependent thalassemia

American journal of hematology, 2013-05, Vol.88 (5), p.409-415

2013

Volltextzugriff (PDF)

Improvement in Liver Pathology of Patients With β-Thalassemia Treated With Deferasirox for at Least 3 Years

Gastroenterology (New York, N.Y. 1943), 2011-10, Vol.141 (4), p.1202-1211.e3

2011

Volltextzugriff (PDF)

Redefining thalassemia as a hypercoagulable state

Annals of the New York Academy of Sciences, 2010-08, Vol.1202 (1), p.231-236

2010

Volltextzugriff (PDF)

Cholelithiasis in thalassemia major

European journal of haematology, 2009-01, Vol.82 (1), p.22-25

2009

Volltextzugriff (PDF)

Hematologic malignancies in thalassemia: Adding new cases to the repertoire

American journal of hematology, 2017-05, Vol.92 (5), p.E68-E70

2017

Volltextzugriff (PDF)

Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development

Expert review of hematology, 2021-07, Vol.14 (7), p.633-644

2021

Volltextzugriff (PDF)

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study

Annals of hematology, 2013-11, Vol.92 (11), p.1485-1493

2013

Volltextzugriff (PDF)

Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study

Blood cells, molecules, & diseases, 2016-03, Vol.57, p.23-29

2016

Volltextzugriff (PDF)

Development of a new disease severity scoring system for patients with non-transfusion-dependent thalassemia

European journal of internal medicine, 2016-03, Vol.28, p.91-96

2016

Volltextzugriff (PDF)

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox

European journal of haematology, 2014-06, Vol.92 (6), p.521-526

2014

Volltextzugriff (PDF)

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes

Drug design, development and therapy, 2016-01, Vol.10, p.4073-4078

2016

Volltextzugriff (PDF)

Deferasirox demonstrates a dose‐dependent reduction in liver iron concentration and consistent efficacy across subgroups of non‐transfusion‐dependent thalassemia patients

American journal of hematology, 2013-06, Vol.88 (6), p.503-506

2013

Volltextzugriff (PDF)

1 – 25 von 222

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(209)
Mit Volltextzugriff
(180)

Publikationsform

Sprache

Englisch
(222)
Japanisch
(14)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(140)
Science & Technology
(140)
Humans
(139)
Hematology
(102)
Male
(85)
Adult
(81)
Female
(80)
Biological And Medical Sciences
(55)
Medical Sciences
(53)
Middle Aged
(44)
Hematologic And Hematopoietic Diseases
(39)
Anemias. Hemoglobinopathies
(36)
Diseases Of Red Blood Cells
(36)
Adolescent
(35)
Thalassemia
(35)
Beta-Thalassemia - Therapy
(28)
Beta-Thalassemia - Complications
(27)
Child
(24)
Young Adult
(23)
Iron Overload
(21)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Anemia in Clinical Practice—Definition and Classification: Does Hemoglobin Change With Aging?

β-Thalassemias

CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia

A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia

Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up

Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in β-thalassemia

New therapeutic targets in transfusion-dependent and -independent thalassemia

β-Thalassemias. Reply

New insights into transfusion-related iron toxicity: Implications for the oncologist

Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload

Αlpha-thalassemia: A practical overview

The autophagy-activating kinase ULK1 mediates clearance of free α-globin in β-thalassemia

Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia

Treating iron overload in patients with non‐transfusion‐dependent thalassemia

Improvement in Liver Pathology of Patients With β-Thalassemia Treated With Deferasirox for at Least 3 Years

Redefining thalassemia as a hypercoagulable state

Cholelithiasis in thalassemia major

Hematologic malignancies in thalassemia: Adding new cases to the repertoire

Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study

Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study

Development of a new disease severity scoring system for patients with non-transfusion-dependent thalassemia

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox

Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes

Deferasirox demonstrates a dose‐dependent reduction in liver iron concentration and consistent efficacy across subgroups of non‐transfusion‐dependent thalassemia patients

Suchergebnisse filtern